Dodge & Cox Has $3.25 Billion Stock Position in Sanofi $SNY

Dodge & Cox lessened its holdings in Sanofi (NASDAQ:SNY) by 3.9% during the third quarter, HoldingsChannel reports. The fund owned 68,931,747 shares of the company’s stock after selling 2,786,568 shares during the quarter. Sanofi accounts for about 1.8% of Dodge & Cox’s investment portfolio, making the stock its 21st biggest holding. Dodge & Cox’s holdings in Sanofi were worth $3,253,578,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in SNY. Brighton Jones LLC boosted its stake in Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares in the last quarter. Finally, Savant Capital LLC boosted its position in shares of Sanofi by 17.1% during the second quarter. Savant Capital LLC now owns 8,423 shares of the company’s stock valued at $407,000 after buying an additional 1,227 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $43.60 on Friday. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. The stock has a fifty day simple moving average of $46.85 and a two-hundred day simple moving average of $48.24. Sanofi has a 1-year low of $43.34 and a 1-year high of $59.17. The firm has a market cap of $106.34 billion, a price-to-earnings ratio of 12.11, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. Barclays lowered Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $62.67.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.